Summary
J-Pharma Co.,Ltd. is a development-stage drug discovery company with no operating revenue. The focus of 2Q results is therefore the pace of spending against the full-year operating expense plan of JPY 2,841M, and the cash position funding it. The first checkpoint is how standalone 2Q R&D expenses moved QoQ, given site activation for the Beacon-BTC trial and progress in the US Phase 1 trial of JPH034. On September 25, within the 2Q period, the company signed a non-binding license term sheet for JPH034 with a European company. Investors will look for an update on progress toward the company's target of "establishing a commercialization scheme in FY3/27." The AMED subsidy (up to JPY 1.5B) and the expansion of Beacon-BTC into Japan and South Korea were announced after 2Q period-end and will affect P&L from 3Q onward. How these items are reflected in the guidance in the 2Q earnings release will be key to assessing the funding burden in 2H.
Key Points for Next Quarter
| Key Points & Focus | Implications |
|---|---|
Expense ProgressCumulative 1H R&D expenses vs. full-year plan, and standalone 2Q trend | 1Q R&D expenses were JPY 487M, or 19.2% of the full-year plan of JPY 2,536M (our estimate). The standalone 2Q level will indicate how heavily spending is skewed toward 2H as the Phase 3 trial ramps up. |
Financial PositionCash and deposits and advance payments at 1H period-end | Cash and deposits stood at JPY 3,726M at 1Q-end, down JPY 724M from the prior fiscal year-end. We will assess this balance against the remaining recurring loss of JPY 2,277M implied by the full-year plan (our estimate). |
Business DevelopmentProgress from the JPH034 license term sheet toward a definitive agreement | The company expects to establish a commercialization scheme for JPH034 in FY3/27, but this is not reflected in guidance. A definitive agreement could change the assumption of zero operating revenue in FY3/27. |
GuidanceIncorporation of the AMED subsidy and Japan/South Korea expansion into full-year guidance | The full-year plan sets both operating loss and recurring loss at JPY 2,841M, assuming no non-operating income. The accounting treatment of the subsidy and any guidance revision will determine the 2H loss level. |
Clinical DevelopmentBeacon-BTC site activation and investigator-initiated trial progress | Activation of 15 US sites was completed as of August 2026. Operating revenue from nanvuranlat is expected from FY3/28 onward, after completion of Part A. |
Key Issues from Previous Results (FY3/27 1Q Results)
1Q posted no operating revenue, with an operating loss of JPY 570M, a recurring loss of JPY 564M, and a quarterly net loss of JPY 561M. Full-year guidance (recurring loss of JPY 2,841M) was maintained, putting recurring loss progress at 19.9% (our estimate). The company described both the Beacon-BTC trial and the JPH034 US Phase 1 trial as "progressing smoothly as planned." In 2Q, beyond spending pace and cash balance, the focus is how partnering and subsidy-driven measures to ease the funding burden are reflected in guidance.
1. R&D Expense Progress vs. Plan and Spending Pace
- Prior Quarter: 1Q R&D expenses were JPY 487M, or 19.2% of the full-year plan of JPY 2,536M (our estimate).
- Focus This Quarter: We will check standalone 2Q R&D expenses as Beacon-BTC site expansion and JPH034 Phase 1 progress. Advance payments rose JPY 159M in 1Q, so a possible shift of expense recognition into later periods is also a focal point.
- Key Metrics: Cumulative 1H R&D expenses vs. full-year plan; standalone 2Q R&D expenses vs. 1Q; SG&A progress against the full-year plan of JPY 304M (27.2% as of 1Q, our estimate).
2. Cash Position and Financial Health
- Prior Quarter: Cash and deposits were JPY 3,726M at 1Q-end (down JPY 724M from the prior fiscal year-end), with an Equity Ratio of 84.2%.
- Focus This Quarter: We will track the cash balance against the remaining recurring loss of JPY 2,277M implied by the full-year plan (our estimate). We will also check whether the capital reduction and deficit offset, effective August 11, is reflected in the 1H balance sheet. This is a reclassification within net assets and does not change total net assets.
- Key Metrics: Cash and deposits at 1H period-end; advance payments balance; changes in net assets and Equity Ratio vs. the prior fiscal year-end.
3. Progress Toward a Commercialization Scheme for JPH034
- Prior Quarter: The company expects to establish a commercialization scheme for JPH034 in FY3/27, but has not reflected it in guidance as terms remain undetermined. The first patient in the US Phase 1 trial was dosed on March 22, 2026, and the trial is progressing as planned.
- Focus This Quarter: A non-binding license term sheet was signed on September 25, within the 2Q period. Being non-binding, it has no direct impact on 2Q P&L. We want to check the status of negotiations toward a definitive agreement and how this is addressed in the earnings release. If a definitive agreement is signed, upfront payments and similar items would be recognized in the accounting period following execution.
- Key Metrics: Any guidance revision; changes in disclosure regarding expected operating revenue recognition; progress commentary on JPH034 Phase 1.
4. Incorporation of the AMED Subsidy and Japan/South Korea Expansion into Guidance
- Prior Quarter: The full-year plan sets both operating loss and recurring loss at JPY 2,841M, assuming no non-operating income. In FY3/26, the company booked non-operating income of JPY 1,110M, and the recurring loss of JPY 2,636M came in below the operating loss of JPY 3,710M.
- Focus This Quarter: The AMED grant award (October 5) and the Japan/South Korea expansion plan (October 14) both occurred after 2Q period-end, so their P&L impact will appear from 3Q onward. We will check the accounting treatment of the subsidy and any guidance revision in the 2Q earnings release. We will also assess the net impact of higher costs from the Japan/South Korea expansion against subsidy income.
- Key Metrics: Any revision to the full-year recurring loss forecast of JPY 2,841M; references to the subsidy and Japan/South Korea expansion in the guidance assumptions.
5. Nanvuranlat Clinical Development Milestones
- Prior Quarter: Beacon-BTC was initiated in December 2025, and activation of 15 US sites was completed as of August 2026. The investigator-initiated trial in combination with immune checkpoint inhibitors (JON-2404-B) dosed its first patient in July 2026.
- Focus This Quarter: We will check the number of activated sites, patient enrollment progress, and preparations for an investigator-initiated trial in KRAS-mutant colorectal cancer. The timing of Part A completion directly underpins the assumption of operating revenue recognition from FY3/28 onward.
- Key Metrics: Number of activated sites disclosed in the earnings release; progress commentary on investigator-initiated trials; maintenance of the expected Part A completion timing.
Key Timely Disclosures This Quarter
- 2026/10/14Decision to Expand Part A of the Global Phase 3 Trial "Beacon-BTC" of Nanvuranlat to Japan and South Korea - The company plans to leverage AMED support to build clinical data while containing its funding burden. As the decision came after 2Q period-end, the cost impact is a 3Q-onward item to monitor.
- 2026/10/05Selection for AMED's "Global R&D Support Program for Intractable and Rare Disease Treatments" - Beacon-BTC qualified for subsidy support of up to JPY 1.5B. This is a non-dilutive funding source, and the focus is how it is incorporated into guidance and accounted for in the 2Q earnings release.
- 2026/09/25Execution of a Non-Binding License Term Sheet for JPH034 with a European Biotech Company - The scope covers worldwide development and commercialization excluding Japan, South Korea, Taiwan, and ASEAN. This marks meaningful progress toward the company's target of establishing a commercialization scheme this fiscal year, though monetization depends on executing a definitive agreement.
Previous Quarter Results (FY3/27 1Q Actual)
The company operates a single drug discovery segment targeting LAT1 (L-type amino acid transporter 1), developing novel therapies for cancer and autoimmune diseases. Lead asset nanvuranlat (biliary tract cancer) is in the global Phase 3 Beacon-BTC trial. JPH034 (secondary progressive multiple sclerosis) is in a US Phase 1 trial, and discovery research on next-generation LAT1 inhibitors is running in parallel. For FY3/27, the company expects no operating revenue and plans operating expenses of JPY 2,841M (R&D expenses of JPY 2,536M and SG&A of JPY 304M). No YoY comparison is available for 1Q, as the company did not prepare quarterly financial statements for the prior-year period. Losses tracked broadly in line with an even pace against the full-year plan.
| Item | Amount | YoY | vs. Company Plan | Notes |
|---|---|---|---|---|
| Operating Revenue | - | - | - | None recorded (none in full-year plan) |
| Operating Income | -JPY 570M | - | - | R&D expenses of JPY 487M; SG&A of JPY 82M |
| Recurring Profit | -JPY 564M | - | - | Interest income of JPY 5M |
| Quarterly Net Income | -JPY 561M | - | - | Gain on reversal of stock acquisition rights of JPY 3M; impairment loss of JPY 0M |
| EPS | -JPY 31.22 | - | - | Full-year EPS forecast of -JPY 158.08 |
Progress vs. Full-Year Plan (Recurring Profit Basis): 19.9% (Prior-Year Period: -)
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.